| Host: |
Goat |
| Applications: |
Pep-ELISA/IHC/ICC |
| Reactivity: |
Human/Mouse/Dog/Pig |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-RANBPM/RANBP9 (C-Term) is suitable for use in ELISA, Immunohistochemistry and Immunocytochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
IHC-3µg/ml, 10µg/mlELISA-antibody detection limit dilution 1:16000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
RANBP9 |
| Gene ID: |
10048 |
| Uniprot ID: |
RANB9_HUMAN |
| Immunogen Region: |
C-Term |
| Accession Number: |
NP_005484.2 |
| Specificity: |
This product is also expected to recognize the centrosome-associated truncated isoform RANBPM (BAA23216.1). |
| Immunogen Sequence: |
GSCAFATVEDYLH |
| Post Translational Modifications | Phosphorylated in response to stress. Can be phosphorylated by the cleaved p110 form of CDC2L1 (p110C). Ubiquitinated. Polyubiquitination targets the protein for rapid degradation via the ubiquitin system. Can be deubiquitinated by USP11. |
| Function | May act as scaffolding protein, and as adapter protein to couple membrane receptors to intracellular signaling pathways (Probable). Acts as a mediator of cell spreading and actin cytoskeleton rearrangement. Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1. May be involved in signaling of ITGB2/LFA-1 and other integrins. Enhances HGF-MET signaling by recruiting Sos and activating the Ras pathway. Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but not affect estrogen-induced transactivation. Stabilizes TP73 isoform Alpha, probably by inhibiting its ubiquitination, and increases its proapoptotic activity. Inhibits the kinase activity of DYRK1A and DYRK1B. Inhibits FMR1 binding to RNA. |
| Protein Name | Ran-Binding Protein 9Ranbp9Bpm-LBpm90Ran-Binding Protein MRanbpmRanbp7 |
| Database Links | Reactome: R-HSA-373760Reactome: R-HSA-5673001Reactome: R-HSA-8851805 |
| Cellular Localisation | CytoplasmNucleusCell MembranePeripheral Membrane ProteinThe Unphosphorylated Form Is Predominantly CytoplasmicA Phosphorylated Form Is Associated With The Plasma Membrane |
| Alternative Antibody Names | Anti-Ran-Binding Protein 9 antibodyAnti-Ranbp9 antibodyAnti-Bpm-L antibodyAnti-Bpm90 antibodyAnti-Ran-Binding Protein M antibodyAnti-Ranbpm antibodyAnti-Ranbp7 antibodyAnti-RANBP9 antibodyAnti-RANBPM antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
